Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Ilhem Messaoudi · UNIVERSITY OF CALIFORNIA-IRVINE · 2019 · $173,809 — Alcohol use disorder (AUD) contributes significantly to disease burden and mortality in the United States, with an annual healthcare cost of $223 billion and a death toll of nearly 88,000. Current methods to assess alcohol intake rely primarily on self-report surveys or biochemical measures of liver…
Rachel Adria Katzenellenbogen · INDIANA UNIVERSITY INDIANAPOLIS · 2019 · $196,875 — Human papillomavirus (HPV) affects up to 75% of adults and is categorized as high risk (HR) or low risk (LR) based on its association with cancer. Although there are preventive vaccines against specific HPV genotypes, immunizations have had poor uptake and completion. This leaves many women and men …
REN SUN · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2019 · $390,000 — Project Summary Influenza A virus causes disease in 5-20% of the population with over 200,000 hospitalizations annually in US. The antigen drift and shift of influenza virus pose a serious challenge for flu vaccination program. Although IFN response is known as the first important host defending mec…
Peter Deak · UNIVERSITY OF CHICAGO · 2019 · $61,610 — Project Abstract: Dendritic cell (DC) antigen uptake and presentation is a crucial initial step in establishing adaptive immune responses. This project will characterize a small sub-set of DCs, called hyper-responder DCs, which display enhanced antigen uptake, immune activation and potentially initi…
Laimonis A. LAIMINS · NORTHWESTERN UNIVERSITY AT CHICAGO · 2019 · $344,835 — PROJECT SUMMARY Human papillomaviruses (HPV) are the causative agents of cervical, anal and many oral cancers. While prophylactic vaccines to prevent HPV infections have been developed, there is no effective therapeutic treatment for existing HPV lesions. It is therefore of critical importance to un…
SIMON R BEST · JOHNS HOPKINS UNIVERSITY · 2019 · $196,433 — Dr. Simon Best is a junior faculty member in the Department of Otolaryngology – Head and Neck Surgery at the Johns Hopkins School of Medicine where his clinical practice is dedicated to voice and airway disorders. With the support of this Mentored Career Development Award, Dr. Best seeks to better u…
Ronald G Collman · UNIVERSITY OF PENNSYLVANIA · 2019 · $3,512,603 — CFAR Overview ABSTRACT This competing renewal application for the Penn Center for AIDS Research (CFAR) builds on an outstanding record of dynamic scientific leadership, organizational structure, resources and infrastructure that advance HIV/AIDS research across the integrated campus of the Universit…
Gabriel D Victora · ROCKEFELLER UNIVERSITY · 2019 · $454,516 — PROJECT SUMMARY/ABSTRACT Germinal centers (GCs) are site of antibody somatic hypermutation (SHM) and affinity maturation, and are therefore essential for effective humoral immune responses to pathogens. Efficient affinity maturation in GCs requires that B cells cycle between two different cell state…
Sina A Gharib · UNIVERSITY OF WASHINGTON · 2019 · $871,221 — PROJECT SUMMARY Melioidosis, a tropical infection commonly manifesting as acute pneumonia and sepsis in humans, is caused by the Gram-negative Tier 1 select agent Burkholderia pseudomallei and represents a global public health threat with an estimated 165,000 cases and 89,000 deaths annually worldwi…
Paul Michael Armistead · UNIV OF NORTH CAROLINA CHAPEL HILL · 2019 · $456,823 — DESCRIPTION (provided by applicant): Chronic and acute leukemias are responsible for ~25,000 deaths annually in the US - a mortality rate that represents ~5% of all cancer related deaths. While leukemias are susceptible to antigen-specific T-cell mediated cytotoxicity, leukemia antigen (LA) di…
Richard B Kennedy · MAYO CLINIC ROCHESTER · 2019 · $777,489 — PROJECT SUMMARY/ABSTRACT This application is a request for funding of a research program focused on understanding the factors associated with waning immune response to mumps vaccine. Waning immunity to mumps is a public health concern and a major obstacle in the control and elimination of mumps dise…
Beatriz MA Fontoura · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2019 · $500,998 — DESCRIPTION (provided by applicant): Influenza viruses cause approximately 36,000 deaths annually in the United States and ~500,000 deaths worldwide per year. Strains that are extremely pathogenic have been responsible for high numbers of deaths worldwide, such as the 1918 pandemic which led to…
Joseph Patti · AGILVAX, INC. · 2019 · $845,852 — Agilvax’s AX09 is an Immunotherapy for Triple-Negative Breast Cancer: Agilvax is developing cancer immunotherapies and vaccines with its proprietary virus-like-particle (VLP) platform technology. Agilvax’s lead product, AX09, is an immunotherapy for triple-negative breast cancer (TNBC) targeting can…
Susan Leilani Fink · UNIVERSITY OF WASHINGTON · 2019 · $69,244 — Project Summary Zika virus (ZIKV) is a recently recognized global health threat due to the wide geographic distribution of risk and potential for severe consequences of infection. There remains no antiviral in clinical use for ZIKV, or any flavivirus, and many unanswered questions regarding the basi…
Nan-ping Peter Weng · NATIONAL INSTITUTE ON AGING · 2019 · $446,172 — A number of hallmarks of immune aging have been identified but underpinning causes are not fully understood. We analyzed three parameters (telomere length, inflammatory cytokines, and antibody titer to CMV) of immune system aging through a longitudinal analysis of 465 subjects ranging in age from 21…
Bernard Moss · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2019 · $772,992 — Poxviruses encode enzymes and factors needed for transcription and replication of their genomes within the cytoplasm of infected cells. Vaccinia virus, the prototypic member of the poxvirus family, provides a unique system for combining biochemical and genetic approaches for investigating mechanisms…
RICHARD CHILDS · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · 2019 · $3,775,841 — Approximately 19 years ago, we initiated the first ever clinical trail investigating allogeneic stem cell transplantation in patients with treatment refractory metastatic renal cell carcinoma (RCC). Definitive evidence for an allogeneic graft-versus-RCC effect has been demonstrated with complete reg…
George N. Pavlakis · DIVISION OF BASIC SCIENCES - NCI · 2019 · $1,436,310 — An important goal of this project continues to be the generation and testing of maximally efficient expression vectors for specific antigens. Our hypothesis is that the DNA vaccine dose is suboptimal for many human applications; therefore, increased efficiency is necessary for practical human DNA va…
THOMAS F GAJEWSKI · UNIVERSITY OF CHICAGO · 2019 · $221,729 — ABSTRACT The main purpose of the Human Immunologic Monitoring and Current Good Manufacturing Practice (HIM- cGMP) Facility is to provide support to investigators at the University of Chicago Medicine Comprehensive Cancer Center (UCCCC) who conduct immunotherapy clinical trials through preparing vacc…
Leaf Huang · UNIV OF NORTH CAROLINA CHAPEL HILL · 2019 · $445,923 — Project 1 Abstract Cutaneous melanoma accounts for the majority (~75%) of skin cancer deaths. Despite the recent improvements in prevention and early detection, approximately 20% of patients with melanoma still die from the diseases. Patients with metastases have a poor prognosis and a very shor…